» Articles » PMID: 6457925

Lymphoid Cells Infiltrating Human Pulmonary Tumors: Effect of Intralesional BCG Injection

Overview
Specialty Oncology
Date 1981 Nov 1
PMID 6457925
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor-infiltrating lymphocytes (TIL) and regional lymph node lymphocytes (LNL) were isolated by mechanical disaggregation and density gradient centrifugation from 30 untreated human lung tumors and 12 BCG-injected human lung tumors. Lymphocyte populations were characterized by their ability to form erythrocyte (E)-rosettes, erythrocyte-antibody-complement, and erythrocyte-antibody gamma-rosettes, by their proportion of esterase-staining cells, and by their responses in mixed lymphocyte culture (MLC), cell-mediated lympholysis (CML). and natural killer (NK) assays. TIL from untreated tumors had low proportions of E-rosetting cells (mean, 27.3%), relatively high proportions of "null" cells, and poor responses in MLC-CML and NK assays. There were no significant differences between primary lung tumors and lung metastases in rosettes, MLC-CML responses, or NK activity. In contrast, TIL from tumors injected with BCG 14 days before resection had higher proportions of E-rosetting cells (47.8%) and vigorous MLC-CML and NK responses. LNL from 11 patients with untreated tumors had higher proportions of E-rosetting cells (40.5%) than LNL from 9 patients with BCG-injected tumors (35.0%) and LNL from patients with untreated tumors had higher responses than LNL from treated patients in MLC-CML assays. These results suggest that the BCG injection induced an infiltration of functionally reactive NK and T-cells at the tumor site without an associated increased activity of T-cells from regional lymph nodes.

Citing Articles

Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?.

Kazemi M, Sadri M, Najafi A, Rahimi A, Baghernejadan Z, Khorramdelazad H Front Immunol. 2022; 13:1018962.

PMID: 36389779 PMC: 9651159. DOI: 10.3389/fimmu.2022.1018962.


In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial.

Economou J, Belldegrun A, Glaspy J, Toloza E, Figlin R, Hobbs J J Clin Invest. 1996; 97(2):515-21.

PMID: 8567975 PMC: 507045. DOI: 10.1172/JCI118443.


Manipulation of host resistance in cancer therapy.

Baldwin R Springer Semin Immunopathol. 1982; 5(2):113-25.

PMID: 6755781 DOI: 10.1007/BF00199791.


Immunology of tumor infiltrating lymphocytes.

Holmes E Ann Surg. 1985; 201(2):158-63.

PMID: 3155935 PMC: 1250634. DOI: 10.1097/00000658-198502000-00004.


Modification of natural killer activity of lymphocytes infiltrating human lung cancers.

Anderson T, Ibayashi Y, Holmes E, Golub S Cancer Immunol Immunother. 1987; 25(1):65-8.

PMID: 3109739 PMC: 11038989. DOI: 10.1007/BF00199303.